Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?
Epstein-Barr virus
Hodgkin lymphoma
oncolytic viruses
virotherapy
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
03 10 2021
03 10 2021
Historique:
pubmed:
9
6
2021
medline:
26
10
2021
entrez:
8
6
2021
Statut:
ppublish
Résumé
Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outcomes, and new treatment strategies are needed for these young adults. There are several well-documented cases in the medical literature on hematologic cancer remission following natural human viral infections. Therefore, hoping to reproduce these spontaneous tumor regressions, researchers have been investigating various viruses with oncolytic properties. There is a high rationale for using virotherapy in the treatment of Hodgkin lymphoma, in which tumor cells are often infected with the Epstein-Barr virus. Modern viral technologies and current knowledge about the relationship between viruses and cancer could accelerate the discovery of effective viral oncolytic therapies. This article reviews the use of oncolytic viruses as innovative therapies for treating Hodgkin lymphoma.
Identifiants
pubmed: 34101538
doi: 10.1080/21645515.2021.1924521
pmc: PMC8437539
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3502-3510Références
Curr Pathobiol Rep. 2018;6(4):247-263
pubmed: 30595970
Eur J Cancer. 2019 Jul;115:47-56
pubmed: 31082693
Cell Death Dis. 2020 Jun 25;11(6):485
pubmed: 32587256
Blood. 2018 Jul 5;132(1):17-22
pubmed: 29716887
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Oncolytic Virother. 2015 Jan 23;4:13-23
pubmed: 27512666
J Clin Oncol. 2018 May 10;36(14):1428-1439
pubmed: 29584546
J Immunol. 2005 Mar 1;174(5):3051-8
pubmed: 15728519
Vaccine. 2013 Sep 6;31(39):4252-8
pubmed: 23726825
Nat Biotechnol. 2012 Jul 10;30(7):658-70
pubmed: 22781695
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Blood. 2019 Aug 15;134(7):591-596
pubmed: 31186275
Haematologica. 2020 Feb 13;105(11):2664-2666
pubmed: 33131257
Hematol Oncol. 1993 Jul-Aug;11(4):187-93
pubmed: 8144133
Mol Ther. 2010 Feb;18(2):251-63
pubmed: 20029399
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Sci. 2017 May;108(5):1007-1012
pubmed: 28267244
Nat Med. 2000 Aug;6(8):879-85
pubmed: 10932224
Oncotarget. 2016 May 24;7(21):30523-35
pubmed: 27105521
Front Oncol. 2017 Jun 26;7:136
pubmed: 28695111
N Engl J Med. 2010 Aug 12;363(7):640-52
pubmed: 20818855
Blood. 2000 Sep 1;96(5):1889-99
pubmed: 10961891
Blood. 2017 May 4;129(18):2471-2478
pubmed: 28270452
Neuro Oncol. 2017 Apr 1;19(4):493-502
pubmed: 27663389
Oncologist. 2017 May;22(5):585-591
pubmed: 28438889
J Clin Oncol. 2003 Oct 1;21(19):3601-8
pubmed: 12913100
J Clin Oncol. 2016 Aug 1;34(22):2619-26
pubmed: 27298410
Cochrane Database Syst Rev. 2017 May 25;5:CD007941
pubmed: 28541603
Oncoimmunology. 2019 Mar 28;8(6):e1581528
pubmed: 31069150
Gene Ther. 2012 Oct;19(10):988-98
pubmed: 22071969
Mol Ther. 2015 Oct;23(10):1630-40
pubmed: 26112079
Oncotarget. 2018 Jan 12;9(16):12971-12981
pubmed: 29560124
J Clin Pathol. 2007 Dec;60(12):1342-9
pubmed: 18042690
J Clin Oncol. 2018 Apr 10;36(11):1128-1139
pubmed: 29315015
Sci Transl Med. 2014 Mar 5;6(226):226ra32
pubmed: 24598590
J Clin Oncol. 2018 Jun 10;36(17):1658-1667
pubmed: 28981385
Cancer Res. 2001 Nov 1;61(21):7882-8
pubmed: 11691808
Sci Rep. 2017 May 24;7(1):2396
pubmed: 28539588
J Clin Oncol. 2001 Dec 1;19(23):4314-21
pubmed: 11731514
Nat Rev Cancer. 2014 Aug;14(8):559-67
pubmed: 24990523
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Blood. 2006 Oct 1;108(7):2280-9
pubmed: 16757686
Oncoimmunology. 2015 Dec 8;5(1):e1115641
pubmed: 26942095
Recent Pat CNS Drug Discov. 2009 Jan;4(1):1-13
pubmed: 19149710
J Clin Oncol. 1999 Feb;17(2):534-45
pubmed: 10080597
J Clin Invest. 2019 May 1;129(5):2071-2087
pubmed: 31042161
J Clin Oncol. 2014 Mar 10;32(8):798-808
pubmed: 24344220
Blood. 2015 Jun 11;125(24):3778-88
pubmed: 25904246
Exp Hematol. 2006 Jun;34(6):713-20
pubmed: 16728275
J Clin Pathol. 2002 Mar;55(3):162-76
pubmed: 11896065
Front Oncol. 2020 Sep 09;10:1786
pubmed: 33014876
Mol Ther Oncolytics. 2016 Dec 14;4:31-40
pubmed: 28345022
EBioMedicine. 2016 Jul;9:31-36
pubmed: 27407036
J Clin Invest. 2000 May;105(9):1169-72
pubmed: 10791988
Clin Transl Oncol. 2019 Aug;21(8):1093-1103
pubmed: 30739242
Curr Cancer Drug Targets. 2007 Mar;7(2):141-8
pubmed: 17346105
J Clin Oncol. 1999 Jan;17(1):222-9
pubmed: 10458237
Mediterr J Hematol Infect Dis. 2009 Nov 24;1(2):e2009013
pubmed: 21416003
Transl Cancer Res. 2012 Jun;1(2):4-14
pubmed: 22924158
Oncolytic Virother. 2018 Jul 31;7:65-77
pubmed: 30105219
J Clin Oncol. 2012 Jun 20;30(18):2183-9
pubmed: 22454421
Curr Top Microbiol Immunol. 2009;330:213-41
pubmed: 19203112
Lancet. 1981 May 16;1(8229):1112
pubmed: 6112483
Br J Haematol. 2007 Apr;137(2):133-41
pubmed: 17391493
Nat Rev Immunol. 2018 Aug;18(8):498-513
pubmed: 29743717
Clin Lymphoma. 2003 Sep;4(2):104-11
pubmed: 14556682
Br J Haematol. 2002 Oct;119(1):122-4
pubmed: 12358914
Front Immunol. 2014 Feb 24;5:74
pubmed: 24605114
Leukemia. 2009 Dec;23(12):2313-7
pubmed: 19865109
Adv Virol. 2012;2012:798526
pubmed: 22312365
Nat Immunol. 2008 May;9(5):503-10
pubmed: 18425107
J Pathol. 1992 Jan;166(1):1-5
pubmed: 1311374
Lancet. 1971 Mar 20;1(7699):593
pubmed: 4100922
Am J Pediatr Hematol Oncol. 1993 May;15(2):162-8
pubmed: 8498641
Clin Cancer Res. 2010 Aug 1;16(15):4005-15
pubmed: 20670951
JAMA Oncol. 2017 Jun 1;3(6):841-849
pubmed: 27441411
Nat Rev Drug Discov. 2015 Sep;14(9):642-62
pubmed: 26323545
Virchows Arch. 2019 Aug;475(2):175-180
pubmed: 31203443
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Mol Ther. 2015 Mar;23(3):602-8
pubmed: 25531693